1
|
Cutruzzulà R, Laudicina S, Bagalà A, Caroti L, Bartiromo M, Gianassi I, Moscarelli L, Di Maria L, Larti A, Allinovi M, Antognoli G, Cirami CL. De novo collapsing glomerulopathy after kidney transplantation: Description of two cases. Clin Nephrol Case Stud 2023; 11:66-71. [PMID: 37114160 PMCID: PMC10127260 DOI: 10.5414/cncs110887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 02/07/2023] [Indexed: 04/29/2023] Open
Abstract
BACKGROUND Among different forms of de novo focal segmental glomerulosclerosis (FSGS), which can develop after kidney transplantation (KTx), collapsing glomerulopathy (CG) is the least frequent variant, but it is associated with the most severe form of nephrotic syndrome, histological findings of important vascular damage, and a 50% risk of graft loss. Here, we report two cases of de novo post-transplant CG. CLINICAL PRESENTATION A 64-year-old White man developed proteinuria and worsening of renal function 5 years after KTx. Before the KTx, the patient was affected by an uncontrolled resistant hypertension, despite multiple antihypertensive therapies. Blood levels of calcineurin inhibitors (CNIs) were stable, with intermittent peaks. Kidney biopsy showed the presence of CG. After introduction of angiotensin receptor blockers (ARBs), urinary protein excretion progressively decreased in 6 months, but subsequent follow-up confirmed a progressive renal function decline. A 61-year-old White man developed CG 22 years after KTx. In his medical history, he was hospitalized twice to manage uncontrolled hypertensive crises. In the past, basal serum cyclosporin A levels were often detected above the therapeutic range. Low doses of intravenous methylprednisolone were administered due to the histological inflammatory signs shown on renal biopsy, followed by a rituximab infusion as a rescue therapy, but no clinical improvement was seen. DISCUSSION AND CONCLUSION These two cases of de novo post-transplant CG were supposed to be mainly caused by the synergic effect of metabolic factors and CNI nephrotoxicity. Identifying the etiological factors potentially responsible for de novo CG development is essential for an early therapeutic intervention and the hope of better graft and overall survival.
Collapse
Affiliation(s)
| | - Selene Laudicina
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Alfredo Bagalà
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | | | | | | | | | | | - Aida Larti
- Nephrology Unit, Careggi University Hospital, and
| | | | | | | |
Collapse
|
2
|
Odone L, Lugli G, Bagalà A, Pirolo B, Spatoliatore G, Rosati A. MO910: Anti-COVID-19 Vaccination and Haemodialysis: Safety During the Haemodialysis Session. Nephrol Dial Transplant 2022. [PMCID: PMC9383895 DOI: 10.1093/ndt/gfac084.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND AND AIMS A complex interplay lies between COVID-19 infection and kidney disease. Patients with COVID-19 are at an increased risk of acute kidney injury (AKI), while CKD patients represent a population at a high risk of mortality from COVID-19 [1]. For 3 years, our hospital has been running an intradyalitic vaccination project (HBV, Haemophylus, Pneumococcus, Influenza) for haemodialysis patients. No data regarding the anti-COVID-19 vaccination administered during the dialysis session are available yet. This is a safety study aimed at defining the feasibility of this vaccination protocol. METHOD A total of 186 haemodialysis patients from 3 centres were vaccinated with the Spikevax-Moderna vaccine (Fig. 1). According to Italian law, patients with a COVID-19 infection in the previous 12 months received only one dose. The administration was performed between 1 and 2 h after the start of the dialysis session. Data regarding mild adverse events were collected. In 117 patients, a titration of the anti-RBD S1 antibodies of the virus spike antigen was performed 1 month after the completion of the vaccination [2]. Therefore, a new titration was obtained after 3 months in 50 patients. RESULTS Of the 117 patients, 65 (55.5%) were male, with a mean age of 69.2 ± 13.1 years. Of these, 25 patients (21.3%) showed mild adverse events without compromising dialysis administration. No serious adverse events took place. Seroconversion was noticed in 111 patients (94.9%) after 1 month, with a mean anti-RBD S1 antibody titer of 751.1 ± 610.5 BAU/mL. When a new titration was performed after 3 months, the titer decreased to 203.1 ± 134.3 BAU/mL (t-test; P = 0.005). CONCLUSION Intradialytic vaccination is a procedure with an excellent safety profile that may be implemented in dialysis settings. Further studies should be permormed to confirm these results.
Collapse
Affiliation(s)
- Ludovica Odone
- Università di Firenze, Department of Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Firenze, Italy
| | - Gianmarco Lugli
- Università di Firenze, Department of Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Firenze, Italy
| | - Alfredo Bagalà
- Università di Firenze, Department of Biomedical Experimental and Clinical Sciences "Mario Serio", University of Florence, Firenze, Italy
| | - Biagio Pirolo
- Nephrology Unit––USL Toscana Centro––Ospedale San Jacopo, Pistoia, Italy
| | | | - Alberto Rosati
- Nephrology Unit––USL Toscana Centro––Ospedale San Giovanni di Dio, Firenze, Italy
| |
Collapse
|
3
|
Cirillo L, Somma C, Allinovi M, Bagalà A, Ferro G, Di Marcantonio E, Bellelli S, Dallari LA, Ballo P, Dattolo PC. Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis. Sci Rep 2021; 11:7463. [PMID: 33811227 PMCID: PMC8018957 DOI: 10.1038/s41598-021-86769-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 03/15/2021] [Indexed: 01/02/2023] Open
Abstract
In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data exist in NDD-CKD patients. Primary objective of this study was to retrospectively evaluate the efficacy of FCM compared with oral ferrous sulfate for the treatment of iron-deficiency anemia in a cohort of NDD-CKD patients, considering also the treatment costs. This was a monocentric, retrospective observational study reviewing 349 NDD-CKD patients attending an outpatient clinic between June 2013 and December 2016. Patients were treated by either FCM intravenous infusion or oral ferrous sulfate. We collected serum values of hemoglobin, ferritin and transferrin saturation (TSAT) and ESAs doses at 12 and 18 months. The costs related to both treatments were also analysed. 239 patients were treated with FCM intravenous infusion and 110 patients with oral ferrous sulfate. The two groups were not statistically different for age, BMI and eGFR values. At 18 months, hemoglobin, serum ferritin and TSAT values increased significantly from baseline in the FCM group, compared with the ferrous sulfate group. ESAs dose and rate of infusion decreased only in the FCM group. At 18 months, the treatment costs, analysed per week, was higher in the ferrous sulfate group, compared with the FCM group, and this was mostly due to a reduction in ESAs prescription in the FCM group. Routine intravenous FCM treatment in an outpatient clinic of NDD-CKD patients results in better correction of iron-deficiency anemia when compared to ferrous sulfate. In addition to this, treating NDD-CKD patients with FCM leads to a significant reduction of the treatment costs by reducing ESAs use.
Collapse
Affiliation(s)
- Luigi Cirillo
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Chiara Somma
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Marco Allinovi
- Nephrology, Dialysis and Transplant Unit, Careggi University Hospital, Florence, Italy
| | - Alfredo Bagalà
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Giuseppe Ferro
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Elio Di Marcantonio
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Stefania Bellelli
- Health Technology Assessment and Management (HTAM) Research Area, IRES Piemonte, Torino, Italy
| | - Lorenzo Antonio Dallari
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Piercarlo Ballo
- Cardiology Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy
| | - Pietro Claudio Dattolo
- Nephrology and Dialysis Unit, Santa Maria Annunziata Hospital, Bagno a Ripoli, Florence, Italy.
| |
Collapse
|
4
|
Bartiromo M, Borchi B, Botta A, Bagalà A, Lugli G, Tilli M, Cavallo A, Xhaferi B, Cutruzzulà R, Vaglio A, Bresci S, Larti A, Bartoloni A, Cirami C. Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19). Transpl Infect Dis 2020; 22:e13286. [PMID: 32279418 PMCID: PMC7262190 DOI: 10.1111/tid.13286] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2020] [Accepted: 03/31/2020] [Indexed: 02/01/2023]
Abstract
During the novel coronavirus pandemic, organ transplant recipients represent a frail susceptible category due to long-term immunosuppressive therapy. For this reason, clinical manifestations may differ from general population and different treatment approaches may be needed. We present the case of a 36-year-old kidney-transplanted woman affected by Senior-Loken syndrome diagnosed with COVID-19 pneumonia after a contact with her positive mother. Initial symptoms were fatigue, dry cough, and coryza; she never had fever nor oxygen supplementation. Hydroxychloroquine and lopinavir/ritonavir were started, and the antiviral drug was replaced with darunavir/cobicistat after 2 days for diarrhea. Immunosuppressant levels were closely monitored, and we observed very high tacrolimus trough levels despite initial dose reduction. The patient was left with steroid therapy alone. The peculiarity of clinical presentation and the management difficulties represent the flagship of our case report. We stress the need for guidelines in transplant recipients with COVID-19 infection with particular regard to the management of therapy.
Collapse
Affiliation(s)
| | - Beatrice Borchi
- Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
| | - Annarita Botta
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Alfredo Bagalà
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Gianmarco Lugli
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Marta Tilli
- Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Annalisa Cavallo
- Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
| | | | | | - Augusto Vaglio
- Department of Biomedical, Experimental and clinical Sciences "Mario Serio", University of Florence, Florence, Italy.,Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy
| | - Silvia Bresci
- Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy
| | - Aida Larti
- Nephrology Unit, Careggi University Hospital, Florence, Italy
| | - Alessandro Bartoloni
- Infectious and Tropical Diseases Unit, Careggi University Hospital, Florence, Italy.,Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
| | - Calogero Cirami
- Nephrology Unit, Careggi University Hospital, Florence, Italy
| |
Collapse
|
5
|
Zullo C, Dallari L, Bagalà A, Somma C, Ferro G, Burgio L, Dattolo P. P1857SALT CONSUMPTION, LIFESTYLE AND PROTEINURIA IN A HETEROGENEOUS YOUNG POPULATION. Nephrol Dial Transplant 2020. [DOI: 10.1093/ndt/gfaa142.p1857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background and Aims
Obesity, hypertension, smoke, high dietary salt intake and physical inactivity are the main modifiable risk factors for chronic kidney disease, that affects about 9-10% of Italian people. About daily salt intake, the World Health Organization recommends a maximum consumption of 5 grams of salt per day. In Italy, most people consume too much salt – on average 8-10 grams per day or around twice the recommended maximum level of intake. Aim of this study was to investigate dietary habits and lifestyle of the heterogeneous students population of “Scuola Carabinieri di Firenze” (attended by people coming from all Italian regions) and their relations with urinary abnormalities.
Method
from November 2018 to March 2019 we collected anamnestic and anthropometric data, blood pressure measurements and body cellular mass (BCM) of 257 young subjects (152 males, 105 females; mean age 32 + 11 yy).
We determinated sodium, chlorine and protein excretion on a spot urine sample in addition to plasma creatinine levels. Statistical analyses were performed using SPSS.
Results
We analyzed preliminary data of urinary sodium excretion (UNa), proteinuria (Up) and hematuria (Urbc) of all the subjects. Fifty-five percent of them had a UNa higher than 100 mmol/L (approximately equivalent to a dietary salt intake of 6 grams/day). In these subjects with higher salt consumption, Up and Urbc, measured by urine dipstick, were detectable in 32% and 21% respectively. In subjects with lower salt intake (less than 6 grams/day), Up and Urbc were 0% and 5% respectively.
To determine if there was an association between our variables, we used Pearson correlation coefficient. We found that UNa was directly related to Up (r 0.26, p 0.002), age (r 0.22 p 0.011) and diastolic blood pressure (DBP, r 0.22, p 0.012). We also found that poor exercise (r -0.15, p 0.7) and low lean body mass percentage (r -0.15, p 0.7) were inversely related to UNa.
Conclusion
high dietary salt intake is associated with elevated blood pressure and proteinuria in a young and “healthy” population. Hypertension and proteinuria are both known risk factors for the development of chronic kidney disease. Wrong dietary habits and lifestyles must be detected and corrected in order to prevent nephropathy onset.
Collapse
Affiliation(s)
- Claudia Zullo
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Lorenzo Dallari
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Alfredo Bagalà
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Chiara Somma
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Giuseppe Ferro
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Lorenzo Burgio
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| | - Pietro Dattolo
- S. M. Annunziata Hospital, Internal Medicine, Nephrology, Firenze, Italy
| |
Collapse
|
6
|
Liguori M, Tagarelli G, Romeo N, Bagalà A, Spadafora P. Identification of a patient affected by "Juvenile-chronic" Tay Sachs disease in South Italy. Neurol Sci 2016; 37:1883-1885. [PMID: 27351546 DOI: 10.1007/s10072-016-2646-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2015] [Accepted: 06/22/2016] [Indexed: 10/21/2022]
Affiliation(s)
- M Liguori
- Institute of Biomedical Technologies, National Research Council, Section of Bari, Bari, Italy
| | - G Tagarelli
- Institute of Neurological Sciences, National Research Council, c/da Burga, 87050, Piano Lago di Mangone, CS, Italy
| | - N Romeo
- Institute of Neurological Sciences, National Research Council, c/da Burga, 87050, Piano Lago di Mangone, CS, Italy
| | - A Bagalà
- Institute of Neurological Sciences, National Research Council, c/da Burga, 87050, Piano Lago di Mangone, CS, Italy
| | - Patrizia Spadafora
- Institute of Neurological Sciences, National Research Council, c/da Burga, 87050, Piano Lago di Mangone, CS, Italy.
| |
Collapse
|
7
|
Arabia G, Zappia M, Bosco D, Crescibene L, Bagalà A, Bastone L, Caracciolo M, Scornaienghi M, Quattrone A. Body weight, levodopa pharmacokinetics and dyskinesia in Parkinson's disease. Neurol Sci 2002; 23 Suppl 2:S53-4. [PMID: 12548340 DOI: 10.1007/s100720200066] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
We conducted a pharmacokinetic study in 164 patients with sporadic Parkinson's disease (PD) to address the relationship between body weight and levodopa pharmacokinetics. Patients underwent an oral acute levodopa test with 250 mg levodopa and pharmacokinetic variables were further assessed. Plasmatic levodopa area under the curve (AUC-l) and body weight were significantly and inversely correlated. Women were significantly lighter and more dyskinetic than men, and had greater AUC-l values. Our data suggest that during long-term treatment, lighter PD patients, especially women, may receive a greater cumulative dosage of levodopa per kilogram of body weight. This could explain gender differences for the development of levodopa-induced peak-dose dyskinesias observed during the course of the disease.
Collapse
Affiliation(s)
- G Arabia
- Institute of Neurology, University of Catanzaro, Policlinico Mater Domini, Via T. Campanella, I-88100 Catanzaro, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Zappia M, Crescibene L, Bosco D, Arabia G, Nicoletti G, Bagalà A, Bastone L, Napoli ID, Caracciolo M, Bonavita S, Di Costanzo A, Gambardella A, Quattrone A. Anti-GM1 ganglioside antibodies in Parkinson's disease. Acta Neurol Scand 2002; 106:54-7. [PMID: 12067330 DOI: 10.1034/j.1600-0404.2002.01240.x] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES To determine whether anti-GM1 antibodies are increased in Parkinson's disease (PD). METHODS Serum immunoglobulin M (IgM) and IgG anti-GM1 antibodies were detected by enzyme-linked immunosorbent assay (ELISA) in 147 patients with PD and in 186 age-matched normal control subjects. Sera were assayed at initial dilution of 1:800 for IgM and 1:200 for IgG and were considered positive at absorbance values exceeding the value of 0.05 for IgM and 0.1 for IgG. RESULTS Forty patients with PD (27.2%) had sera positive for IgM anti-GM1 antibodies, whereas only five normal controls (2.7%) resulted positive (P < 0.0001). Most of patients (75%) with positive sera had a tremor-dominant form of PD. Only two patients with PD (1.4%) and none of normal controls had sera positive for IgG anti-GM1 antibodies. CONCLUSION A consistent portion of parkinsonians, mainly with a tremor-dominant form of PD, may have increased circulating IgM anti-GM1 antibodies.
Collapse
Affiliation(s)
- M Zappia
- Institute of Neurology, University of Catanzaro, Catanzaro, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Nicoletti G, Crescibene L, Scornaienchi M, Bastone L, Bagalà A, Napoli ID, Caracciolo M, Quattrone A. Plasma levels of vitamin E in Parkinson's disease. Arch Gerontol Geriatr 2001; 33:7-12. [PMID: 11461717 DOI: 10.1016/s0167-4943(01)00092-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Oxidative stress has been implicated as a major contributor to selective neuronal death in Parkinson's disease (PD). Vitamin E is an antioxidant that may protect the brain from free radical-induced oxidative damage. It is, therefore, reasonable to hypothesize that low levels of vitamin E concentrations may increase the risk of developing PD. To elucidate the possible role of vitamin E in the pathogenesis of PD, we assessed the plasma levels of vitamin E, measured by high-performance liquid chromatography (HPLC), in 54 patients with PD. Vitamin E concentrations were also assessed in 93 age and sex matched normal individuals. The mean plasma levels of vitamin E did not differ significantly between these two groups (22.5+/-8.15 &mgr;mol/l for PD patients and 21.0+/-7.9 &mgr;mol/l for controls). The results of our study suggest that plasma vitamin E concentrations do not play a major role in the pathogenesis of PD.
Collapse
Affiliation(s)
- G Nicoletti
- Institute of Experimental Medicine and Biotechnology, National Research Council, Contrada Burga, I-87050 Piano Lago di Mangone, Cosenza, Italy
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Aguglia U, Annesi G, Pasquinelli G, Spadafora P, Gambardella A, Annesi F, Pasqua AA, Cavalcanti F, Crescibene L, Bagalà A, Bono F, Oliveri RL, Valentino P, Zappia M, Quattrone A. Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sjögren syndrome. Ann Neurol 2000. [PMID: 10665502 DOI: 10.1002/1531-8249(200002)47] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
We report on 2 brothers (aged 19 and 12 years) with Marinesco-Sjögren syndrome who also had very low serum vitamin E concentrations with an absence of postprandial chylomicrons. The molecular study ruled out ataxia with isolated vitamin E deficiency, abetalipoproteinemia, and hypobetalipoproteinemia. The electron microscopy of the intestinal mucosa was consistent with a chylomicron retention disease. We speculate that both chylomicron retention disease and Marinesco-Sjögren syndrome are related to defects in a gene crucial for the assembly or secretion of the chylomicron particles, leading to very low serum levels of vitamin E.
Collapse
Affiliation(s)
- U Aguglia
- Institute of Neurology, School of Medicine, University of Catanzaro, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Qualtieri A, De Marco EV, Crescibene L, Andreoli V, Bagalà A, Scornalenchi M, Brancatl C, Greco CM. Hb J-Wenchang-Wuming or alpha 11(A9)Lys-->Gln in an Italian woman. Hemoglobin 1995; 19:277-80. [PMID: 8537231 DOI: 10.3109/03630269509005814] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- A Qualtieri
- Centro Studi delle Microcitemie, Cosenza, Italia
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Tagarelli A, Bagalà A, Brancati C. Phosphoglucomutase-1 subtypes in the Albanian ethnic minority of the province of Cosenza (Calabria-Southern Italy): Presence of a new variant. ACTA ACUST UNITED AC 1995. [DOI: 10.1007/bf02444605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
13
|
Affiliation(s)
- E V De Marco
- Istituto di Medicina Sperimentale e Biotecnologie, CNR, Cosenza, Italia
| | | | | | | | | | | |
Collapse
|
14
|
Tagarelli A, Mazzei R, Bagalà A, Bastone L, Qualtieri A, Brancati C. Genetic polymorphism at the phosphoglucomutase 1 (PGM1) locus in Cosenza Province (Calabria--southern Italy). Gene Geogr 1991; 5:107-11. [PMID: 1840293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
1315 school-boys of the Cosenza province (Calabria - southern Italy) were subtyped for the PGM1 locus. Three subsamples were examined, two from the Tyrrhenian and the Ionian coasts, respectively, and one from the internal part of this province. The PGM1*1S, PGM1*2S and PGM1*2F gene frequency estimates obtained for the population of the Ionian coast were significantly different from those of the tyrrhenian coast. Since the three subsamples were of similar size, estimates weighted also with the respective population sizes were calculated.
Collapse
Affiliation(s)
- A Tagarelli
- Istituto per lo Studio delle Malattie Ereditarie e Carenziali-CNR, Cosenza, Italy
| | | | | | | | | | | |
Collapse
|
15
|
Qualtieri A, Crescibene L, Bagalà A, De Marco EV, Bria M, Brancati C. Hb F-Cosenza or G gamma 25(B7)Gly----Glu: a new fast-moving fetal hemoglobin variant. Hemoglobin 1991; 15:509-15. [PMID: 1726095 DOI: 10.3109/03630269109027898] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A fast-moving gamma chain variant was discovered in the cord blood of a newborn during a screening program carried out in the northern region of Calabria, Southern Italy. The structural analysis showed a Gly----Glu substitution at position 25 of the G gamma chain indicating a new fetal hemoglobin variant that was named Hb F-Cosenza.
Collapse
Affiliation(s)
- A Qualtieri
- Centro Studi delle Microcitemie Cosenza, Italy
| | | | | | | | | | | |
Collapse
|